secwatch.observer — SEC 8-K summary
======================================

Issuer:     Erasca, Inc. (ERAS)
CIK:        0001761918
Form:       8-K
Filed at:   2023-05-25T23:59:59+00:00
Accession:  0000950170-23-024292
Event type: other_material
Sentiment:  neutral
Materiality: 0.60
Item codes: 8.01
LLM model:  deepseek-v4-flash:cloud@v2

Erasca reports early data on ERAS-007 combos: 40% response in BRAFm CRC; stops palbociclib combo in KRASm tumors
--------------------------------------------------------------------------------

- ERAS-007 + encorafenib + cetuximab in BRAF V600E CRC: 40% response (2/5) at 100mg BID-QW, 29% overall across doses.
- Combination generally well-tolerated with mostly low-grade AEs; one DLT (Grade 3 macular edema) at highest dose.
- ERAS-007 + palbociclib showed no clinical activity in KRAS/NRAS mutant CRC and KRASm PDAC; company will not pursue combo.
- Additional Phase 1b HERKULES-3 data in BRAF-mutated CRC expected between H2 2023 and H1 2024.
- PK exposures of ERAS-007, encorafenib, cetuximab comparable to monotherapy, no significant drug-drug interactions.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023024292/0000950170-23-024292-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1761918/000095017023024292/eras-20230525.htm
  HTML page:      https://secwatch.observer/filing/0000950170-23-024292

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer